WELLINGTON MANAGEMENT GROUP LLP 13D and 13G filings for Reata Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-09-09 10:26 am Sale | 2022-08-31 | 13G | Reata Pharmaceuticals, Inc. RETA | WELLINGTON MANAGEMENT GROUP LLP | 1,508,638 4.780% | -2,744,339 (-64.53%) | Filing |
| 2022-02-04 09:22 am Sale | 2021-12-31 | 13G | Reata Pharmaceuticals, Inc. RETA | WELLINGTON MANAGEMENT GROUP LLP | 4,252,977 13.510% | -92,747 (-2.13%) | Filing |
| 2021-02-04 09:57 am Purchase | 2020-12-31 | 13G | Reata Pharmaceuticals, Inc. RETA | WELLINGTON MANAGEMENT GROUP LLP | 4,345,724 13.990% | 1,324,800 (+43.85%) | Filing |
| 2020-04-09 08:53 am Purchase | 2020-03-31 | 13G | Reata Pharmaceuticals, Inc. RETA | WELLINGTON MANAGEMENT GROUP LLP | 3,020,924 10.820% | 628,250 (+26.26%) | Filing |